Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Gonadorelin

GnRH, Luteinizing Hormone-Releasing Hormone, LHRH, Factrel

Quick Stats
Studies 192
Trials 100
Score 3
2025 pubmed

Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin.

Han. Quanquan Q; Jiao. Yunlong Y; Cai. Ruisi R; You. Jiahuan J; Chen. Xiaofeng X; Zhang. Wentao W; Wang. Hao H; Ji. Huimin H; Yu. Xinmin X; Xu. Yinuo Y; Fu. Fenghua F; Zhang. Xuemei X; Yu. Jicheng J; Zhang. Yuqi Y; Gu. Zhen Z

Key Findings

  • The microneedle patch can pierce the outer skin layer and release goserelin microspheres into deeper tissue.
  • Goserelin is released continuously for up to 28 days, matching the duration of standard injectable implants.
  • Therapeutic effects and safety of the patch are comparable to conventional intramuscular goserelin administration.

Practical Outcomes

  • For DIY health enthusiasts, this shows a potential route to deliver GnRH‑type peptides without daily injections, though the technology is still experimental and not commercially available. It may guide future self‑administered, long‑acting hormone protocols, but users should await more data and regulatory clearance before trying it.

Summary

Researchers created a tiny needle patch that dissolves quickly and drops goserelin‑containing microspheres into the skin, releasing the drug steadily for about a month. It works as well as the usual painful muscle shots and appears safe, offering a less invasive way to give this hormone‑blocking peptide.

Abstract

Goserelin is widely employed as a form of androgen deprivation therapy in the management of prostate cancer. Given the chronic nature of hormonal therapy, sustained and long-term drug administration is essential to ensure therapeutic efficacy. Goserelin is often formulated as sustained-release implants or microspheres requiring intramuscular injections. Both delivery methods necessitate administration by trained healthcare personnel and are frequently associated with poor patient compliance due to procedural invasiveness and considerable discomfort. Herein, we developed a goserelin microsphere-loaded microneedle (GSR-MN) patch as a minimally invasive alternative. The microneedles exhibit robust mechanical strength and rapid dissolution properties, enabling them to effectively penetrate the stratum corneum and facilitate the delivery of goserelin microspheres into the underlying skin tissue. The GSR-MN patch demonstrates excellent biocompatibility and biosafety, and is capable of sustaining goserelin release over a 28-day period. The therapeutic outcomes were comparable to those of conventional intramuscular goserelin microsphere administration, offering a promising strategy to improve patient adherence and reduce treatment-associated discomfort.

Study Information

Provider

pubmed

Year

2025

Date

2025-11-08T00:00:00.000Z

DOI

10.1016/j.jconrel.2025.114397

References

27